We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Compugen Discovers Biomarker Candidate for Diagnosis of Ovarian Cancer and Signs Collaboration Agreement
News

Compugen Discovers Biomarker Candidate for Diagnosis of Ovarian Cancer and Signs Collaboration Agreement

Compugen Discovers Biomarker Candidate for Diagnosis of Ovarian Cancer and Signs Collaboration Agreement
News

Compugen Discovers Biomarker Candidate for Diagnosis of Ovarian Cancer and Signs Collaboration Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Compugen Discovers Biomarker Candidate for Diagnosis of Ovarian Cancer and Signs Collaboration Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Compugen Ltd. has disclosed the discovery and experimental verification of CGEN-327, a novel molecular biomarker candidate for the diagnosis of ovarian cancer.

CGEN-327 is a previously unknown splice variant of the HE4 (Human Epididymis Protein 4) gene, which is a known biomarker for ovarian cancer. The company also announced that it has entered into a research and license option agreement for the product candidate with a leading diagnostic company. Patent coverage for this discovery is being pursued by Compugen.

Anat Cohen-Dayag, vice president of R&D for Compugen stated, “This is an excellent example of Compugen’s unique “discovery on demand” capabilities. In this case, we were approached by a leading company developing and commercializing immunoassay panels for rapid diagnosis of challenging diseases. Their specific interest was to determine whether any unknown splice variants exist for this known biomarker for ovarian cancer, an objective with a high level of industry interest and past research activity.”

The recently signed collaboration agreement provides Compugen’s partner with an option to obtain worldwide royalty bearing commercialization rights for diagnostic products based on this and novel gene product, with Compugen retaining all therapeutic applications. Financial terms were not disclosed.
Advertisement